EUVIMEDObjevte EUVIMED
Crossref

Ailanthone alleviates septic cardiomyopathy by attenuating MYST histone acetyltransferase 1 (MOF)‐mediated H4K16 lactylation‐driven inflammation

Yu Zhou, Meican Ma, Chong Xu, Mei Wang, Qiulun Lu

British Journal of Pharmacology · 2026-08 · 183 (15) · 4364-4380

DOI: 10.1111/bph.70478 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2026-04-29. Written by Yu Zhou and 4 co-authors. Institution: Clinical Research Center, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing M…. Major MEDLINE topics: Sepsis, Cardiomyopathies, Histones, Histone Acetyltransferases. Cited 1 times so far (Crossref); 35 references. Funded by: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Wuxi People's Hospital.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background and Purpose Elevated circulating lactate is a recognized prognostic biomarker in septic cardiomyopathy (SCM), yet the mechanisms by which it exacerbates cardiac pathology are not fully understood. This study aims to investigate the role of histone lactylation as a novel epigenetic mechanism linking metabolic dysregulation to myocardial dysfunction in sepsis. Experimental Approach The effects of lactate on lipopolysaccharide (LPS)‐induced inflammation and apoptosis were assessed in cardiomyocytes in vitro. The underlying epigenetic mechanism was investigated using CUT&Tag. The role of MYST histone acetyltransferase 1 (MOF) as a lactyltransferase was determined through siRNA knockdown, co‐immunoprecipitation and fluorescence co‐localization assays. Furthermore, ailanthone (AIL), a specific hexokinase 2 (HK2) inhibitor identified through virtual screening, was evaluated for its therapeutic potential in a murine model of sepsis. Key Results Lactate enhanced LPS‐induced cardiomyocyte inflammation and apoptosis. Mechanistically, lactate upregulated histone H4 lysine 16 lactylation (H4K16la). This modification was enriched at the promoters of the CXCL8 and CCL2 genes to drive their transcriptional activation. We further identified MOF as a novel lactyltransferase directly catalysing H4K16la. In vivo, inhibition of HK2 with AIL attenuated myocardial injury and improved cardiac function in septic mice. Conclusion and Implications Our findings reveal a pathogenic axis wherein lactate‐driven H4K16la, mediated by MOF, promotes inflammatory gene expression in SCM. This identifies the lactate‐H4K16la pathway as a potential therapeutic target for mitigating septic cardiomyopathy.

Subjects

MeSH terms (MEDLINE)

SepsisCardiomyopathiesHistonesHistone AcetyltransferasesInflammationAnimalsMaleMiceMice, Inbred C57BLLipopolysaccharidesMyocytes, CardiacHumansApoptosis

Author keywords

ailanthonehistone H4inflammationlactylationseptic cardiomyopathy

Substances

HistonesHistone AcetyltransferasesLipopolysaccharidesKat8 protein, mouse

Authors and institutions

  • Clinical Research Center, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, China.
  • Department of Rheumatology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, China.
  • Department of Cardiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, China.
  • Jiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.

Funding

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province
  • Wuxi People's Hospital
  • Wuxi Health Commission for Youth
  • Medical Center Foundation of Nanjing Medical University

Cite

APA

Zhou, Y., Ma, M., Xu, C., Wang, M., & Lu, Q. (2026). Ailanthone alleviates septic cardiomyopathy by attenuating MYST histone acetyltransferase 1 (MOF)‐mediated H4K16 lactylation‐driven inflammation. British Journal of Pharmacology, 183(15), 4364-4380. https://doi.org/10.1111/bph.70478

Vancouver

Zhou Y, Ma M, Xu C, Wang M, Lu Q. Ailanthone alleviates septic cardiomyopathy by attenuating MYST histone acetyltransferase 1 (MOF)‐mediated H4K16 lactylation‐driven inflammation. British Journal of Pharmacology. 2026;183(15):4364-4380. doi:10.1111/bph.70478

BibTeX
@article{Zhou2026,
  author = {Zhou, Yu and Ma, Meican and Xu, Chong and Wang, Mei and Lu, Qiulun},
  title = {Ailanthone alleviates septic cardiomyopathy by attenuating MYST histone acetyltransferase 1 (MOF)‐mediated H4K16 lactylation‐driven inflammation},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {15},
  pages = {4364--4380},
  doi = {10.1111/bph.70478}
}
Start for free →